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Abstract
an idea for a new combination therapy will be described herein. it is a proposition to combine viral 
and bacterial anticancer therapies and make them fight cancer in concert. we analyzed biological an-
ticancer therapies and found overlapping advantages and disadvantages which led us to the conclusion 
that the combination therapy has the potential to create a new therapeutic quality. it is surprising how 
many weaknesses of viral anticancer therapy are the strengths of bacterial anticancer therapies and 
the other way round. we review the facts behind this concept and try to assess its value. we propose 
a few strategies how to combine these two therapies but as far as the review can go, final answers 
will have to come from the experiments. This review is the first attempt to describe a new strategy and 
understand the means for this idea but also to raise new questions and discuss new ways to look at 
anti-cancer treatment.
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Introduction
Despite all the research and the countless attempts to 
find a perfect anti-cancer therapy, the most successful and 
effective therapy remains to be tumor resection. In the 19th 
century clinicians observed that viral or bacterial infection 
[1] ⁠ could lead to partial tumor regression [2] ⁠ and some-
times, could even cure a patient. Limited understanding 
of microbiology, the discovery of radioactivity and later, 
first chemotherapies made the biological therapies less at-
tractive. Bacteria and viruses remained in the shadow of 
the main stream of science until the critical advancement 
in microbiology and genetic engineering from the 1950s to 
the 1980s. In the meantime many chemotherapeutics were 
developed, isolated success stories gave some hope but 
were rarely confirmed in large clinical trials. At the dawn 
of chemotherapy, science moved to antibodies, developed 
gene therapy, immune therapy and gave a second chance to 
genetic engineering of microorganisms. Hundreds of pro-
teins had been tested and a few were a minor breakthrough. 
Herceptin, an antibody against HER2 receptor, with rela-
tively low side effects led to a substantial improvement in 
the patient’s outcome. Unfortunately, it is only useful in 
some HER2 positive breast cancer patients and a few oth-
er HER2 positive cancers. Most immunotherapies which 
include bacteria or viruses have also failed except for one. 
Namely, Bacillus Calmette-Guerin (BCG) therapy is an 
accepted bacterial immunotherapy against non-invasive 
bladder cancer and it significantly decreases tumor recur-
rence and metastases. Biological anti-cancer therapies still 
conceal its potential. Both bacterial and viral anti-cancer 
therapies have the hypothetical advantages which have 
never been found in any described therapy. In this review 
we want to propose a new strategy based on combination-
al bacterial and viral anti-cancer therapies. Both of them 
present advantages and disadvantages, but they fail to fight 
cancer when used separately. We will discuss how to cou-
ple these two therapies and how they support one another.
Bacteria and viruses
Since the very beginning of modern medicine in the 
19th century physicians observed tumor regression coin-
ciding with infections. It was a time when the basics of 
microbiology were being settled and a distinction between 
bacteria and viruses was not so clear. Biological cancer 
therapies using viruses or bacteria proved to be beneficial 
to some patients but lost the struggle for attention with 
the rise of chemotherapy and radiotherapy. Half a century 
had to pass until microbiology was developed enough and 
genetic modification started to be possible. After many 
years of research on chemotherapy and radiotherapy sci-
entists did not find the perfect drug. In the search of better 
therapies, science returned to the abandoned ideas. Using 
modern techniques improves previous weaknesses to carve 
potential therapies. Luckily both bacteria and viruses are 
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fairly easy for genetic manipulation and there are plenty 
possible species to research.
Viruses
Reports of some patients with regressing tumors af-
ter some infections followed a similar, at that time un-
explainable, pattern. Patients with advanced stages of 
cancer got infected and immediately after the infection, 
the tumor started to shrink. Unfortunately, remission did 
not last for more than a month. Finally, cancer progressed 
and patients died [3] ⁠. Today we have already learned that 
a rapid tumor regression followed by tumor progression 
means viral infection. Tumor relapse occurs because of 
the immune system producing antibodies that clear the 
patient of viruses. Today, even without any serious break-
through, viruses tempt scientists with unique properties. 
Viruses can selectively kill tumor cells. It is possible 
thanks to two major strategies: a) replacing viral promot-
ers with tumor specific promoters [4] ⁠, and b) deleting the 
genes dispensable in cancer cell [5, 6] ⁠. Prostate specific 
promoter has been used to create ARCA (CN706) virus 
which can divide only in cells with PSA (prostate specific 
antigen) expression. There are two important examples of 
oncoviruses with deleted genes: ONYX-015 with E1b-55k 
deletion (p53 binding site) and AdΔ24 without Rb bind-
ing site of E1A (described later). Onyx-015 mutant can 
kill p53 mutants, potentially more than 50% of tumors [7]⁠. 
Cells with p53 mutations are resistant to hypoxia induced 
apoptosis [8, 9] ⁠. Therefore, p53 mutants are even more 
important. It all started with ONYX-015. It has been a clin-
ical failure but has opened a new door to the remarkable 
idea of CRAds, conditionally replicating adenoviruses. 
ONYX-015 had a deletion of E1b-55kDa. In a wild type 
E1b binds to an active p53 and inactivates it to allow viral 
replication. Without E1b the virus can replicate only in 
p53-cells. It makes the virus a perfect bullet for more than 
50% of cancers with a p53 mutation. In recent years we 
could observe a few clinical trials. The most important one 
was ONYX-015. It reached the third stage of clinical trials 
but finally failed to prove its efficacy. Recently, in March 
2013, T-VEC (herpes simplex virus 1 based therapy) has 
successfully passed phase three clinical trials.
Bacteria
William Coley was the first one to go beyond a sheer 
observation; he actually created a therapy based on atten-
uated bacteria. As other clinicians before him he also ob-
served that in cancer patients, staying in beds that were 
previously used by patients with infectious diseases, the 
tumor regression has been observed. At that time people 
knew that diseases could be transmitted so the tumor re-
gression had something to do with the previous patients. 
Coley isolated patient’s bacteria and created a mix of two 
attenuated bacteria called Coley’s Toxin. At that time it 
has been a successful therapy capable of reducing many 
tumors and, sometimes, leading even to a complete tumor 
eradication [10] ⁠. Unfortunately, nobody really knew why 
these therapies worked. Again, for the same reasons as vi-
ruses, bacterial anticancer therapy has been put aside. Pres-
ently, due to the development in microbiology and immune 
system field bacteria regained scientific attention. After 
many years of research on a variety of bacteria, Bacillus 
Calmette-Guerin (BCG), only one has been approved. The 
first and so far the only FDA-approved bacterial therapy 
(BCG) is an unspecific immune stimulator against bladder 
cancer [11] ⁠. Patients with non-muscle invasive bladder 
cancer, about 70% of bladder cancer patients, are treated 
with BCG. Bacillus Calmette-Guerin intravesical injection 
is preceded by endoscopic transurethral tumor resection 
and needs to be performed many times. The exact mech-
anism is not fully understood but it has been shown that 
NK cells [12] ⁠ and cytotoxic T lymphocytes play a crucial 
role [13] ⁠. As a result, up to 60% of patients will become 
tumor free [14] ⁠. First of all, bacteria will be attracted to 
the hypoxic regions of tumors. Growing tumor cannot 
develop healthy vasculature and without one, hypoxic re-
gions appear. Therefore, bacteria of choice are optional or 
obligatory anaerobes [15]⁠ which will limit the spread of the 
bacteria mainly to the tumor tissue. As a result of hypoxia 
and handicapped vascularization, many cells die leaving 
all the debris in the tumor. While choosing potential can-
didates for bacterial anti-cancer therapy it is also import-
ant to choose intracellular bacteria. In this review we will 
concentrate on salmonella typhimurium [16] ⁠ but Listeria 
monocytogenes [17]⁠ is also a very important candidate.
Combined therapies
How can a combination of therapies improve  
the outcome?
Both viruses and intracellular bacteria are evolutionary 
designed to infect the eukaryotic cells, including humans. 
Biological anticancer therapy aims to take advantage of 
these skills in order to kill cancer cells. Unlike any other, 
these skills tempt scientists to try to develop anticancer 
therapy. First of all, both organisms are self-replicating in 
the tumor milieu. As viruses need cells to replicate, they 
can find them in excess in the tumor. If we manage to de-
liver the therapeutic agent into the tumor, viruses and bac-
teria will replicate. It means that we can use lower doses of 
microorganisms and spare the other regions of the organism 
the toxicity and side effects common to other therapies. In 
clinical trials both therapies have been delivered by i.v. in-
jections with a different efficiency. Unfortunately, viruses 
are very effectively cleared from blood by the innate mech-
anisms. For example, AdV-5 (adenovirus type 5), 
after i.v. injection binds to circulating platelets which ag-
gregate and end up in liver sinusoids where they are de-
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graded by Kupfer cells [18-21]⁠. As a result a viral half-life 
is about 2 minutes in mice [22]⁠ and goes up to 12 minutes 
in humans [23] ⁠. After secondary injection resulting in 
a production of antibodies these times get even shorter. On 
the other hand, bacteria, for example salmonella typh-
imurium, have much longer half-life time ranging within 
24 hours both in mice and humans [24, 25]. Animal re-
search suggests also that in contrast to viruses bacteria can 
be re injected. After the first exposure to the pathogen, 
adaptive immunity also takes part in fighting pathogens 
using specific CTLs or antibodies. They are very effective 
means of clearing the blood of any pathogen. However, the 
delivery of therapeutic agent remains a problem because 
high doses may be detrimental and low doses will not pro-
vide sufficient concentration at the tumor. Due to the abil-
ity of active migration, bacteria are very well suited as 
a tumor delivery system [26]⁠. salmonella typhimurium has 
been modified to exhibit chemotaxis towards tumor. It in-
volves modifications of the aspartate receptor and ribose 
receptor which direct bacteria into tumor tissue. There is 
also a serine receptor that makes bacteria prone to pene-
trate the host tissue [16, 27]⁠. Bacterial migration skills can 
be further exploited. Even in the case of initial good deliv-
ery, antiviral antibodies will reach the tumor cells and will 
clear them of viral particles. If we are able to attach the 
virus to the bacteria, intracellular bacteria will give a shel-
ter to the viruses as well. Moreover, bacteria can also over-
come another obstacle faced by viruses, tumor compart-
mentalization. Researchers working with oncolytic viruses 
observed that when virus reaches the tumor, it cannot 
spread into the entire tumor, if there are any fibrous barri-
ers between tumor compartments. Surrounding the tumor 
with fibroblasts is one of the protective methods helping to 
slow down the tumor growth. Growing tumors often find 
a way out and bud. Such a bud creates a new compartment 
which is again surrounded by a fibrous tissue. Even if ef-
fectively delivered, viruses cannot cross these barriers and 
ultimately cannot kill the entire tumor. On the other hand, 
bacteria have the ability to actively migrate and have nev-
er been reported to have a problem in seeding the entire 
tumor. For example, Listeria monocytogenes can migrate 
between infected cells without being exposed to the immu-
nological system [28]⁠. Bacterial motility and natural abili-
ty to dissect fibrous tissue can help to seed the tumor and 
maximize virus distribution. Yet another problem shared 
by all intracellular therapies needs to be solved. In compar-
ison to the surrounding healthy tissue, the tumor has an 
“increased hydrostatic pressure” [18] ⁠. Bacteria chemoat-
tracted by cell debris, composed of necrotic parts of the 
tumor, can migrate against the current produced and by 
hiding inside the tumor cell will remain in the tumor while 
freely floating drugs as well as viruses are pushed out of 
the tumor. Motile bacteria can easily overcome the current 
and seed every tumor niche. The bacterial migratory skill 
comes with another therapeutic advantage, targeting me-
tastases. It is still a matter of debate with counterarguments 
from different experiments but it has been shown that bac-
teria can migrate not only into the main tumor but also 
small metastatic niche [26, 29] ⁠. Eventually clinical trials 
uncover the clinical facts which did not really stand up to 
the promises seen at the beginning [26, 29]. Both of these 
features come from the bacterial tumor tropism. If bacteria 
are so much better why bother with viruses? Bacteria can 
be better at targeting the tumor but viruses have unprece-
dented killing skills. Viruses are not only very effective 
killing mechanisms but the most exciting fact is the ability 
of certain mutants to selectively kill cancer cells. Each type 
of viruses has its unique ability to attack eukaryotic cells. 
Mutants of HSV-1 and Parova virus need dividing cells 
[30, 31] ⁠ while reovirus is dependent on an activated ras 
pathway [32]⁠. After infection viral genetic material has to 
be reproduced inside the cell. The mechanism leading to 
the reproduction is strictly controlled by a host cell gene 
expression. In other words, viral genetic material will be 
expressed only if it contains promoters which can be acti-
vated by host cell machinery. Thanks to genetic engineer-
ing we can modify viruses so that they are able to attack 
only tumor cells. We believe that CRAds are the future of 
oncolytic viruses. Retinoblastoma protein (Rb) is even 
a more promising weapon against cancer than Onyx-15 
was. Retinoblastoma protein guards cell-cycle in normal 
cells. For the cancer cells to multiply, Rb needs to be con-
stantly inactive (phosphorylated Rb = pRb). It can be 
achieved by a direct Rb mutation or mutation in one of 
many Rb activators among which we can find the deadliest 
oncogenes like: p53, p15, CDKs, cyclins, myc, ras and oth-
er crucial oncogenes. As a matter of fact, all human can-
cers have inactivated Rb. Mutated viruses with deleted E1a 
(Rb-binding and inactivating site) are unable to proliferate 
in healthy cells. Healthy cells are additionally protected by 
interferons. Since all types of cancer have to have inacti-
vated Rb it means that not only AdΔ24 is selective to tu-
mor cells but it also has the potential to kill all types of 
cancer. It makes AdΔ24 an ideal candidate for tumor erad-
ication therapy. It is also worth mentioning that these on-
cogenes are called undruggable genes [33] and despite 
a lot of effort there are neither low molecular drugs nor 
proteins targeting these proteins. Moreover, healthy cells 
have an additional mechanism of protection against viral 
infection. Infected cell produces interferon (IFN)-α and 
IFN-β [34]⁠ which acts as an alarm to the neighboring cells. 
To protect from viral infection neighboring cells shut down 
all the metabolic machinery necessary for the virus to rep-
licate. Many cancer cells lack this mechanism and there-
fore are more susceptible to viruses. Viruses and bacteria 
can work in a feedback loop. While multiplying viruses 
lyse the tumor and release cell debris which in turn serve 
as a source of the nutrients for bacterial growth. It is also 
well known that problems in treating cancer come from 
cancer stem cells (CSC) which are often drug resistant. 
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Bacteria and viruses are not specific to any particular anti-
gen and cannot be pumped out of the cell as many drugs 
are. Therefore, biological therapies are equally useful 
against all cancer cells. Some CSCs are rapidly dividing, 
what makes them even more susceptible to viral infections. 
Another problem are senescent cancer cells which are re-
sponsible for tumor regression. These cells remain inactive 
and are very insensitive to any therapy, therefore contrib-
ute to cancer regression after becoming active again. Vi-
ruses will probably spare senescent cells but bacteria, by 
inducing strong immune response, help to clear the re-
maining cells. Additionally, intracellular bacteria may kill 
such a cell on its own.
Immune reaction
Tumors can be divided into immunogenic and non-im-
munogenic ones [35] ⁠. Immunogenic tumors are partly 
susceptible to immunotherapy but, unfortunately, tumor 
immunosuppression and evolution attenuate immune re-
sponse resulting in tumor recurrence. On the other hand, 
we can treat non-immunogenic tumors with chemotherapy 
or radiotherapy which, carefully designed, can lead to can-
cer remission. Again, cancer still holds the advantage by 
metastasizing and evolving out of therapy killing spectrum 
[36, 37] ⁠. All tumors are somewhere on the range between 
those two. The role of bacteria as a immunostimulant is 
to amplify the strength of the immune reaction leading to 
better immunotherapy [38]⁠. Pre-existing immunity can be 
amplified by a cocktail of cytokines like interleukin (IL)-2 
IFN-α, IFN-β or IFN-γ, IL-12, IL-23, GM-CSF and others. 
It is clear when we talk about more immunogenic tumors 
but what happens with less immunogenic tumors? Since 
we are proposing using two pathogens we also expect to 
amplify the reaction against viral antigens expressed on 
cancer cells infected by viruses and expressing E1A an-
tigen [39] ⁠. Cells infected by viruses expose E1A in MHC 
what makes the cell immunogenic and marks it to be killed 
by the immune system [40]⁠. It is a well-established mecha-
nism that cells infected by viruses release interferons IFN 
to warn neighboring cells about threats. It has also been 
shown that salmonella typhimurium infection can give 
similar results and release of IFN from macrophages [41] ⁠ 
leading to necroptosis [42-44] ⁠ and pyroptosis of macro-
phages [45]⁠. Moreover, some type of interferons can addi-
tionally promote an antitumor immune response by recruit-
ing and stimulating NK cells [46]⁠.
For final tumor eradication it is not bacteria that has 
the final word against the tumor. Syngenic tumors in mice 
injected with bacteria regressed. Shortly after tumor dis-
appeared, mice were already bacteria free and the tumor 
shrinkage continued until it was completely cleared out 
[47]⁠. Not were mice only tumor free, they were immunized 
against tumor antigens. It means that bacterial anticancer 
therapy is based on bacteria killing cancer cells in this or 
the other way but also bacteria inducing strong host im-
mune response against cancer cells.
Threats
Before deciding to infect a patient with a pathogen we 
need to consider the risks of using an experimental therapy 
based on pathogens versus the probability of successful 
treatment using standard therapy. This question becomes 
even more important when one considers the use of two 
pathogens. Until we do not know the real reaction of or-
ganisms, this kind of combination should be used only 
when current therapies give no real hopes. Clinical data on 
oncolytic bacteria give no reasons to suspect the threats of 
sepsis but it can never be ruled out so to protect the patient 
we will have to use only bacteria susceptible to antibiotics. 
Similarly with viruses; the immune system can efficiently 
clear the virus out but for the safety it is important to be 
ready to use antiviral serum. Up till now no clinical data 
have shown serious side effects of bacterial or viral thera-
pies. Nevertheless, we have to keep in mind experiments 
done on mice. By accumulating in hypoxic regions of tu-
mors, bacteria gain perfect growing conditions. Murine 
experiments showed that injection of clostridium botuli-
num spores into tumor bearing mice may be lethal [15, 
48]⁠. Luckily, there are many potentially therapeutic bacte-
ria to choose from. For example, salmonella typhimurium 
can equally well accumulate in tumors but while growing 
keep the toxicity low [49] ⁠. Another line of defense is the 
genetic manipulation which prohibits viruses and bacteria 
to infect any other tissue besides the tumor. To insure the 
safety of these mutations and prevent reversed mutations 
it is important to use proper genetic techniques, like delet-
ing genes instead of mutating a part of the gene. We can 
do a lot to prevent all the predicted complications but we 
also stay with an open question how our organisms will 
react to such a coinfection and it will be answered only by 
experiment. Because of the coinfection risk [50]⁠, the final 
therapy will have to be carefully tailored.
Up-to-date experience with neither of these therapies 
showed severe side effects [51] ⁠, or even comparable to 
those observed for chemo- or radiotherapy.
How to merge viral and bacterial 
therapies?
By extracting the best out of two therapies we want to 
maximize the therapeutic result. We propose using bacteria 
as a carrier for viruses. Each pathogen has its role to play. 
Bacteria’s main task is to deliver the virus into the tumor 
and by active migration hide it from the immune system. 
To make it possible the virus will have to be bound or 
fused into the bacteria for example with binding proteins 
like anti-viral scFv regions expressed on bacterial surface.
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If the virus is attached to bacteria they will hide togeth-
er so that the immune system will not clear them out. By 
co-infecting the tumor we would allow viruses to spread 
inside the tumor and use their pinpoint ability to kill can-
cer cells. Since viruses kill by starting a lytic cycle which 
ends up with cell lysis and releasing of about 200 [52]⁠ new 
viruses which subsequently infect neighboring cancer cells 
every lytic cycle, which takes 40 to 48 hours [52]⁠. Sooner 
or later the immune system will develop antibodies against 
viruses. But till then we hope to have the virus well spread 
and hidden together with bacteria. Very recently this idea 
has been partly supported by research done by Cronin et 
al. [53] ⁠. They have combined a non-pathogenic bacteria 
Escherichia coli expressing B18R, with a vesicular stoma-
titis virus (VSV). Bacteria were used to precondition the 
tumor by expressing B18R an antagonist of type I inter-
feron. Blocking type I interferon communication resulted 
in a reduction in tumor growth and prolonged mice sur-
vival [53] ⁠. More supporting data come from clinical and 
microbiological experience. It has been known for decades 
that bacterial and viral coinfection result in a much higher 
morbidity and mortality [54-57].
Conclusions
The idea of combinational therapy presented here de-
scribes unknown possibilities. Both anti-tumor agents can 
act as long as the tumor exists. They survive thanks to the 
most conservative hallmark of cancer, the necrotic, immu-
nosuppressed and hypoxic region of tumor. Unlike any 
drug, viruses can effectively kill cancer cells possessing 
no immunogenic mutations of nuclear proteins: p53 and 
RB [6, 58]⁠. Both p53 and Rb are among so-called undrug-
gable genes, so that neither low molecular drug nor a pro-
tein was found which could kill cells with those mutations. 
Modified viruses have to replicate in such cells to survive 
and cannot do so in non-mutated cells. Viruses can kill 
cancer cells without the contribution of the immune sys-
tem. While viruses selectively attack and kill tumor cells, 
bacteria not only disseminate the virus inside the tumor, 
but they also induce a strong immune response against tu-
mor antigens [59]⁠. By inducing a strong immune response 
against bacterial antigens, they may overcome the immu-
nosuppression produced by tumor cells and tumor support-
ing immune cells: TIL’s, MDSC, TAM and TAN’s, result-
ing in prevailing Th 1 type response [11]. This effect can 
be even stronger when supported by an antiviral response 
which would occur due to the presence of viruses. Properly 
designed bacteria can support this struggle by direct kill-
ing as much as by production of therapeutic proteins, e.g. 
proapoptotic proteins. These actions may possibly be even 
stronger due to the fact that we are dealing with self-repli-
cating agents. Most of our arguments supporting the idea 
of combinational therapy is a result of scientific literature 
analysis. Very recently there has been an article based on 
a very similar idea where authors proved that such a ther-
apy can lead to better results [53]⁠.
Safety issues remain a very important part of the dis-
cussion. Both therapies proved to be safe with no or mild 
side effects but very little is known about possible results 
in a combination therapy. Many crucial questions have to 
be answered: what is the risk that the infection will spread? 
Is there any risk to develop sepsis? Is there a risk of mu-
tations which will turn the therapeutic agents against the 
patient? Do we have working retreat strategies in case in-
fections would break out of control? These and other ques-
tions need to be answered before any serious attempts for 
clinical trials are introduced. Nevertheless, it will have to 
be thoroughly investigated how the human organism reacts 
to double infection [51, 60]⁠.
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